Montelukast (10mg) + Levocetirizine (5mg) + Acebrophylline (200mg) (Medical Monograph)

Overview

A fixed-dose combination (FDC) therapy for the management of moderate to severe allergic respiratory conditions, particularly bronchial asthma and allergic rhinitis. It provides a triple-action approach: Montelukast is a leukotriene receptor antagonist (LTRA) that reduces bronchoconstriction and inflammation; Levocetirizine is a potent second-generation H1-antihistamine that blocks histamine-mediated allergic symptoms; Acebrophylline is a mucolytic and bronchodilator that improves airway clearance and reduces bronchial hyperreactivity. This combination is widely used in the Indian context for its synergistic effect in controlling both upper and lower airway allergic inflammation.

The combination exerts a synergistic effect on the allergic-inflammatory cascade in the respiratory tract. Montelukast selectively blocks the cysteinyl leukotriene type 1 (CysLT1) receptor, inhibiting the action of leukotrienes (LTC4, LTD4, LTE4) which are potent mediators of bronchoconstriction, vascular permeability, and eosinophil recruitment. Levocetirizine is a potent and selective peripheral H1-receptor inverse agonist, preventing histamine-induced symptoms like itching, sneezing, and rhinorrhea. Acebrophylline has a dual action: it acts as a mucolytic by reducing mucus viscosity and secretion, and its metabolite, theophylline, acts as a bronchodilator via non-selective phosphodiesterase (PDE) inhibition and adenosine receptor antagonism, reducing airway hyperresponsiveness.